Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus MEPSEVII.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus MEPSEVII.
IMPOYZ vs MEPSEVII
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
MEPSEVII (vestronidase alfa) is a recombinant form of human beta-glucuronidase that hydrolyzes accumulated glycosaminoglycans (GAGs) in lysosomes, restoring enzymatic activity in patients with Mucopolysaccharidosis VII (Sly syndrome).
100 mg orally twice daily
1 mg/kg administered intravenously once weekly over 4 hours.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 9.4 hours (range 6.3–16.6 hours) in patients with mucopolysaccharidosis VII; supports weekly intravenous dosing.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are recycled or excreted in urine as metabolites.
Category C
Category C
Unknown
Unknown